All In Biotech

NDA 022142 · Mylan Labs LTD

Symfi

Efavirenz, Lamivudine, Tenofovir Disoproxil Fumarate · Oral · Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor; Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor; Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor

Priority review

Last checked: Nov 19, 2026Latest source record: Oct 29, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2018

Mar 22, 2018

Approved uses

1

Original approval plus efficacy supplements

Registered trials

432

116 Phase 3, 6 recruiting

FAERS reports

30

21 serious, 1 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: POST TREATMENT ACUTE EXACERBATIONS OF HEPATITIS B Severe acute exacerbations of hepatitis B have been reported in patients who are co-infected with hepatitis B virus (HBV) and human immunodeficiency virus (HIV-1) and have discontinued lamivudine or tenofovir disoproxil fumarate, two components of SYMFI. Monitor hepatic function closely in these patients and, if appropriate, initiate anti-hepatitis B treatment [see Warnings and Precautions (5.1) ]. WARNING: POST TREATMENT ACUTE EXACERBATIONS OF HEPATITIS B See full prescribing information for complete boxed warning. • Severe acute exacerbations of hepatitis B have been reported in patients who are co-infected with HBV and human immunodeficiency virus (HIV-1) and have discontinued lamivudine and tenofovir disoproxil fumarate. Monitor hepatic function closely in these patients and, if appropriate, initiate anti-hepatitis B...

What it is approved for

From the label in effect Oct 15, 2019.

SYMFI ® (efavirenz, lamivudine and tenofovir disoproxil fumarate) is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adult and pediatric patients weighing at least 40 kg. SYMFI is a three-drug combination of efavirenz (EFV), a non-nucleoside reverse transcriptase inhibitor, and lamivudine (3TC) and tenofovir disoproxil fumarate (TDF), both nucleo(t)side reverse transcriptase inhibitors and is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adult and pediatric patients weighing at least 40 kg. ( 1 )

Mechanism: SYMFI is a fixed-dose combination of antiviral drugs EFV, 3TC, and TDF with antiviral activity against HIV-1 [see Microbiology (12.4) ]. Mechanism of Action Efavirenz EFV is an NNRTI of HIV-1. EFV activity is mediated predominantly by noncompetitive inhibition of HIV-1 reverse transcriptase (RT). HIV-2 RT and human cellular DNA polymerases α, β, γ, and δ are not inhibited by EFV. Lamivudine 3TC is a synthetic nucleoside analogue with activity against HIV-1 and HBV. Intracellularly, 3TC is phosphorylated to its active 5’‑triphosphate metabolite, lamivudine triphosphate (3TC-TP). The principal...

Therapeutic areas: Infectious disease and vaccines · Rare and genetic disease

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • SYMFI · EFAVIRENZ 600MG; LAMIVUDINE 300MG; TENOFOVIR DISOPROXIL FUMARATE 300MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Efavirenz" as an intervention, any sponsor and status, largest first.

All 432 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • anhedonia8
  • anxiety8
  • emotional distress8
  • pain8
  • bone density decreased6
  • foetal exposure during pregnancy4
  • headache4
  • osteoporosis4
  • renal failure4
  • back pain3
  • bone demineralisation3
  • chronic kidney disease3

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20181
20198
20206
20216
20221
20235
20241
20252

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Symfi (Efavirenz/Lamivu/Tenofov Disop)

2024 spending

$645K

Beneficiaries

52

185 claims

Per beneficiary

$12,399

$49.07 per unit

View as table
YearSpending
2020$3,884,953
2021$2,167,284
2022$1,565,258
2023$1,243,781
2024$644,749

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,020 on PubMed

Sponsor: Mylan Labs LTD

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.